Good News For Many Advanced Melanoma Patients: Pharmac Drug Funding Announcement Confirms Better Treatment Options
Melanoma New Zealand welcomes today's news from Pharmac for increased and new access to funded medicines because it's long-awaited good news for many New Zealand patients with advanced melanoma.
It means many New Zealand patients with stage 3B to stage 4 melanoma will now have a much-needed lifeline in their fight against this insidious disease with free access to potentially life-saving and life-extending treatment options.
'Melanoma New Zealand has been engaging with Pharmac advocating for increased funding for treatments for melanoma patients and providing technical expertise. Today's announcement is long overdue, and we are delighted about the difference this will make for patients,' says Andrea Newland, Melanoma New Zealand Chief Executive.
For a long time melanoma patients in New Zealand have had less access to funded treatment options such as immunotherapies and targeted therapies than patients in many other countries including Australia.
'Access to these lifesaving and life-extending melanoma treatments helps bring New Zealand further in line with international standards of care. It empowers melanoma healthcare specialists (and their patients) with a broader range of treatment options, and the ability to provide tailored care,' says Newland.
Specifically, the major steps forward are:
Unless 'inoperable' (unresectable), patients with stage 3B-D have been self-funding or relying on insurance for access to immunotherapy drug Keytruda. Funded Keytruda is now an option for these patients from 1 June 2025.
Additionally, immunotherapy drug Keytruda can be offered to these patients and stage 4 patients before surgery (it can help to shrink tumours), and/or after surgery (reducing the likelihood of the melanoma recurring).
BRAF and MEK inhibitor drugs Tafinlar (dabrafenib) and Mekenist (trametinib) are now available to stage 3B-D and stage 4 patients with BRAF mutant melanoma. This offers another option for targeted treatment for these patients, (who may or may not be undergoing surgery as well).
Finlay (Fin) Bergin is someone who could benefit directly. The 28-year-old Auckland man was diagnosed with stage 3 melanoma on 10 September 2024 and after two surgeries has been paying for the immunotherapy medicine combination of dabrafenib and trametinib, through a combination of personal savings (Fin's had some of his KiwiSaver released), parental and family support, and generous donations through a givealittle page set up by his brother.
Fin says, 'This [funded treatment] will make a huge difference and put me at ease, because the biggest stress since my diagnosis has been money related.'
Melanoma New Zealand is delighted for the many melanoma patients who will benefit from this increased access to funded melanoma medicines, but we also acknowledge those patients for whom this decision may come too late, or who are not eligible or suitable for these treatments.
This funding is a significant step forward. There is more work to be done, and Melanoma New Zealand will continue to advocate for further improvements for all those impacted by melanoma.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
5 days ago
- Scoop
Pharmac Urged To Widen Access To Covid Vaccines
Aotearoa Covid Action (ACA) is calling on Pharmac to reconsider its proposal to award principal supply of Covid-19 vaccines exclusively to Pfizer's Comirnaty, citing concerns over limited access and equity. The group has urged its members and others to support Pharmac maintaining and widening vaccine access to all who want them before the public consultation closes today at 5:00 PM. Pharmac's current proposal would fund only the Comirnaty vaccine, with alternative brands available solely through its Exceptional Circumstances framework. ACA believes this creates an exclusionary barrier that may prevent some people from getting vaccinated or boosted at all. 'If the goal is for as many Kiwis as possible to be vaccinated and boosted, they must feel engaged and empowered. Having a few options does this. Comirnaty is an mRNA vaccine. It is contraindicated for some, and some simply prefer a different, protein-based vaccine such as Novavax. Pharmac should accommodate these needs and preferences instead of promoting a one-size-fits-all model,' says Julia Schiller, a spokesperson for ACA. In its own submission on the proposal, ACA also suggests Pharmac widen the pool of New Zealanders eligible for Covid vaccinations and boosters, noting for example that regular boosters are unavailable to the nearly 2 million Kiwis under the age of 30 and that children under five cannot ordinarily receive any vaccination at all. 'Pharmac itself has acknowledged that protection wanes significantly over time, so it's odd that they are not looking to widen eligibility for boosters. Many of our under-30s would have last had a booster years ago,' said Schiller. The organisation points out that recent New Zealand research identified an 'urgent need to revise New Zealand's eligibility criteria [and] make vaccines available and accessible to younger age groups'. 'The more we learn, the more we see that Covid infections present a potential risk to all the body's organs and systems. Data suggests Long Covid is a real consequence of at least 10% of infections. We simply must do more to protect our tamariki and rangitahi and their teachers, both for their own health and to reduce spread of infections from schools to families to the greater community. We need a diversified and accessible vaccination strategy,' said Schiller. Widening vaccine availability aligns with the third demand of ACA's ongoing petition campaign, which advocates for more accessible vaccinations and boosters, among other measures to slow the transmission of airborne diseases. 'Winter has arrived and with it, a jump in cases of influenza and Covid, in particular the new variant NB.1.8.1,' Schiller added. The World Health Organisation has designated NB.1.8.1 a variant under monitoring. As of 29 May, it accounted for 21.6% of Aotearoa's current Covid cases, according to ESR's wastewater monitoring. 'Pharmac must ensure that a choice of vaccines is not only available but also easily accessible to all, regardless of location or circumstance. Pharmac approved five different formulations of the flu vaccine this year so it seems reasonable to ask they offer a choice of at least two different Covid vaccines.' Aotearoa Covid Action encourages individuals and organizations to email their feedback on the proposal to vaccines@ For more information on Aotearoa Covid Action's stance and to support their petition, visit Aotearoa Covid Action's Website and Clean Air in Schools Petition.
Scoop
31-05-2025
- Scoop
Broken Promise
During the 2023 election campaign, National made a commitment to a significant increase in the funding of cancer drugs. This promise was completely forgotten in Nicola Willis' 2024 Budget but was partly rectified in November due to the ensuing public outcry. At that time Shane Reti, then Minister of Health, stated that 'blood cancers would not be forgotten.' $151million was allocated to Pharmac in 2024 over 4 years to purchase new cancer drugs. However, blood cancer patients have received hardly any of this. Pharmac predicts only about 180 people with blood cancers per annum will benefit from these changes. 'There are more than 2,000 people in NZ living with Chronic Lymphocytic Leukaemia and about half of whom require treatment at any one time. For most of them there is no treatment alternative to outdated medicines. Just 15 Chronic Lymphocytic Leukaemia* patients per annum are expected to benefit from the funding largesse,' said Dr Ruth Spearing, 'and of these 15, 5 approvals are for Bendamustine — a derivative of nitrogen mustard, which was originally developed during WWII and is rarely used in other countries now.' Dr Spearing said 'This is another stark (and, for many, fatal) broken election promise'. *CLL Dr Ruth Spearing, Haematologist and Trustee of CLL Advocates NZ CNZM, FRACP, FRCPA Rob Crozier, Patient and Trustee of CLL Advocates NZ Background New Zealand funds the smallest number of new blood cancer drugs in the OECD and spends less per head of population on drugs when corrected for GDP than ANY other OECD country. This is well below the spending of countries with similar levels of wealth. Not many New Zealanders are aware of this. Pharmac's lack of funding impacts on the ability of Health NZ to treat patients as the less effective intravenous drugs are funded rather than oral alternatives, leading to lack of spaces to treat patients in infusion centres as well as much less effective outcomes.
Scoop
26-05-2025
- Scoop
Schedule Rule Changes Will Improve Continuity Of Cancer Care
Pharmac is proposing a change to the Pharmaceutical Schedule rules, which if agreed, would give New Zealanders with cancer greater continuity of care. Pharmac is consulting on a proposal to amend the rules of the Pharmaceutical Schedule, following the Government's decision to enable access to new publicly funded cancer medicines in private hospitals and clinics from 1 August 2025. 'When Pharmac funds a new cancer medicine, there may be some people who have already started this treatment in a private health care facility. Currently, if this person wants their cancer medicine funded, they need to transition back into the public system during their treatment,' Director Strategy, Policy and Performance Michael Johnson says. Johnson says that the rule change Pharmac is consulting on will enable public hospitals to supply medicines to eligible private facilities and claim a subsidy from Pharmac in the same way as they do for medicines delivered within a public hospital. If approved, from 1 August 2025, public hospitals would be able to supply newly funded cancer medicines (those where funding begins on or after 1 August 2025) to private facilities to administer to their patients, where either: the person is already receiving treatment at the date that their medicine becomes funded by Pharmac, or the person has an approved treatment plan, and is about to start treatment, at the date that the medicine becomes funded by Pharmac. Funded medicine could be supplied to a private facility for the remainder of a person's treatment course, for up to 12 months. 'Your input is valuable and helps us make better decisions. Let us know what you think by 13 June,' Johnson says. Consultation on this proposal opens today and closes on 13 June. All feedback received before the closing date will be considered prior to making a decision on this proposal. Feedback can be emailed to consult@
